Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing its lead candidate ONC010, a nanoparticle-encapsulated polynucleotide kinase phosphatase (PNKP) inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response (DDR) therapy market that is distinct from established PARP inhibitor therapies.
Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has integrated the SynoGraph causal AI platform to support patient stratification, clinical trial design and oncology evidence generation.
Ongoing CMC, IND-enabling and preclinical development activities are intended to support advancement of ONC010 toward planned first-in-human clinical studies. Onco-Innovations is a clinical-stage oncology company focused on advancing a new class of DDR therapies and developing artificial intelligence-driven precision oncology solutions.
The company’s strategy is centered on building a scalable oncology platform supported by proprietary intellectual property, strategic collaborations and integrated development capabilities. In recent years, Onco-Innovations has expanded its operational footprint through acquisitions and research partnerships.
For investors, the latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
